4D Molecular Therapeutics
Clinical trials sponsored by 4D Molecular Therapeutics, explained in plain language.
A biotech developing gene therapies using AAV vectors.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- One-Time gene shot could cut eye injections for wet AMD Results expected Mar 2027 (estimated)
- One shot to save sight? gene therapy aims to cut eye injections for wet AMD Results expected Jun 2027 (estimated) 🚀 Make-or-break
- Inhaled gene therapy aims to fix cystic fibrosis lungs Results expected Jun 2027 (estimated)
-
One-Time gene shot could cut eye injections for wet AMD
Disease control Recruiting nowThis study tests a gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single injection into the eye can safely reduce the need for regular anti-VEGF shots. About 215 adults aged 50 and old…
Phase 1/2 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Inhaled gene therapy aims to fix cystic fibrosis lungs
Disease control Recruiting nowThis phase 1/2 trial tests a single inhaled dose of gene therapy called 4D-710 in 30 adults with cystic fibrosis who cannot take standard modulator drugs. The therapy delivers a working copy of the CFTR gene directly to lung cells. The main goal is to check safety and side effect…
Phase 2 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
One shot to save sight? gene therapy trial aims to end frequent eye injections for wet AMD
Disease control Recruiting nowThis Phase 3 trial tests a single injection of 4D-150, a gene therapy, in 480 adults with wet age-related macular degeneration (AMD). The goal is to see if one treatment can maintain or improve vision and reduce the need for standard anti-VEGF injections like Eylea. Participants …
Phase 3 • Sponsor: 4D Molecular Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC